Drugs / autologous hematopoietic stem cells

Trials 3

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05887167 Mar 2024 → Dec 2026 expected acute lymphoblastic leukemia, diffuse large B-cell lymphoma, large B-cell lymphoma, mantle cell lymphoma +1 Joshua Sasine, MD, PhD Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02282514 Oct 2014 → Aug 2019 classic stiff person syndrome Northwestern University Terminated No outcome recorded
Phase 1/2 NCT00282438 Dec 2003 → Aug 2015 sarcoidosis Northwestern University Terminated No outcome recorded Stop: Enrollment
Comparator or background therapy3 trials
Phase 2/3 NCT01782274 Comparator Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded
Phase 2/3 NCT01782287 Comparator Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded
Phase 2/3 NCT01759810 Comparator Dec 2012 → Dec 2018 glioblastoma NeuroVita Clinic Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as autologous hematopoietic stem cells “Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438 ↗
5

NCT01782287 ↗

NCT01782274 ↗

NCT05887167 ↗

NCT01759810 ↗

NCT02282514 ↗

Known as aHSCs “Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.” NCT05887167 ↗
Action Restore “The purpose of the stem cell infusion is to evaluate whether this treatment will produce a normal immune system that will no longer attack the body.” NCT00282438 ↗
Modality Cell therapy “Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438 ↗
Route Other “Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438 ↗